Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia: Hypoglycemia is the most common adverse effect of all insulins, including NovoLog ®.Adjustments in concomitant anti-diabetic treatment may be needed. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia.Sharing poses a risk for transmission of blood-borne pathogens. Patients using NovoLog ® vials must never share needles or syringes with another person. Never Share a NovoLog ® FlexPen, NovoLog ® FlexTouch, PenFill ® Cartridge, or PenFill ® Cartridge Device Between Patients, even if the needle is changed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |